PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE CLEVER-1 ANTIBODY BEXMARILIMAB IN COMBINATION WITH PD-1 BLOCKADE IN PATIENTS WITH ADVANCED SOLID TUMORS - BEXCOMBO

被引：0
|
作者：
Bono, Petri [1 ]
Jalkanen, Juho [2 ]
Pawlitzky, Inka [2 ]
Fjaellskog, Marie-Louise [3 ]
Ahlin, Cecilia [3 ]
机构：
[1] Univ Helsinki, Helsinki, Finland
[2] Faron Ldt, Turku, Finland
[3] Faron, Boston, MA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0709
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
709
引用
收藏
页码：A742 / A742
页数：1
相关论文
共 50 条
  • [1] A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer
    Bono, P.
    Jaakkola, P.
    Shetty, S.
    Ma, Y. T.
    de Jonge, M. J. A.
    Robbrecht, D.
    Minchom, A. R.
    Pal, A.
    Yap, C.
    Pasanen, A.
    Skytta, T.
    Thibault, A.
    Cruz, R.
    Jalkanen, M.
    Jalkanen, S.
    Hollmen, M.
    Mandelin, J.
    Karvonen, M.
    Koivunen, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S706 - S707
  • [2] Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study
    Xiong, Jianping
    Ouyang, Weiwei
    Yang, Mengxiang
    Gao, Zhenyuan
    Zhou, Huan
    Lou, Hanmei
    Guo, Yabing
    Xu, Zhongyuan
    Zheng, Ling
    Liu, Ying
    Wang, Zhongfeng
    Sun, Ping
    Niyazi, Huerxidan
    Wang, Jianhua
    Chen, Yan
    Zhang, Baihui
    Li, Lingyan
    Kang, Xiaoyan
    Guo, Weijian
    ADVANCES IN THERAPY, 2024, 41 (11) : 4153 - 4171
  • [3] EARLY RESULTS FROM A PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND EFFICACY OF AMG 404, A PROGRAMMED DEATH-1 (PD-1) ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Price, Timothy
    Chawla, Sant
    Falchook, Gerald
    Prenen, Hans
    Lugowska, Iwona
    Subbiah, Vivek
    Monzon, Jose
    Ozawa, Yuichi
    Arkenau, Tobias
    Lima, Caio Rocha
    Kuboki, Yasutoshi
    Nishina, Tomohiro
    Hui, Mun
    Rasmussen, Erik
    Wong, Hansen
    Najmi, Saltanat
    Sadraei, Nooshin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A245 - A245
  • [4] The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis
    Nie, Run-Cong
    Zhao, Chong-Bang
    Xia, Xiao-Wei
    Luo, Ying-Shan
    Wu, Ting
    Zhou, Zhi-Wei
    Yuan, Shu-Qiang
    Wang, Yun
    Li, Yuan-Fang
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [5] PHASE I STUDY OF ANTI PD-1 ANTIBODY ONO-4538 IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Yamamoto, N.
    Nokihara, H.
    Yamada, Y.
    Asahina, H.
    Shibata, T.
    Tamura, Y.
    Seki, Y.
    Honda, K.
    Tanabe, Y.
    Wakui, H.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 26 - 26
  • [6] Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors
    Chen, Chang-Long
    Pan, Qiu-Zhong
    Weng, De-Sheng
    Xie, Chuan-Miao
    Zhao, Jing-Jing
    Chen, Min-Shan
    Peng, Rui-Qing
    Li, Dan-Dan
    Wang, Ying
    Tang, Yan
    Wang, Qi-Jing
    Zhang, Zhi-Ling
    Zhang, Xiao-Fei
    Jiang, Li-Juan
    Zhou, Zi-Qi
    Zhu, Qian
    He, Jia
    Liu, Yuan
    Zhou, Fang-Jian
    Xia, Jian-Chuan
    ONCOIMMUNOLOGY, 2018, 7 (04):
  • [7] Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors
    Liu, Jiajian
    Zhou, Caicun
    Li, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] PHASE 1 STUDY OF THE PORCUPINE (PORCN) INHIBITOR RXC004 IN COMBINATION WITH THE PD-1 INHIBITOR NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Cook, Natalie
    Blagden, Sarah
    Lopez, Juanita
    Sarker, Debashis
    Greystoke, Alastair
    Bashir, Saira
    Skolariki, Aglaia
    ElBadri, Salma
    Morton, Cienne
    OrtegoFranco, Ana
    MohamedKhan, Shybi
    Eagle, Catherine
    Flanagan, Eimear
    Goodwin, Louise
    Phillips, Caroline
    Robertson, Jane
    Tilston, Craig
    Timmis, Helen
    Woodcock, Simon
    Plummer, Ruth
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A752 - A752
  • [9] A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors
    Callahan, Margaret K.
    Ott, Patrick Alexander
    Odunsi, Kunle
    Bertolini, Staphane V.
    Pan, Linda S.
    Venhaus, Ralph Rudolph
    Karakunnel, Joyson Joseph
    Hodi, F. Stephen
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Clinical observation of the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced solid tumors
    Wang, Miao
    Zhen, Hongchao
    Jiang, Xiaoyue
    Lu, Yuting
    Wei, Yuhan
    Jin, Jiangtao
    Li, Qin
    IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (04) : 1584 - 1595
12345